Drugs: entrectinib
FDA Approves Roche's NTRK Fusion Therapy for Solid Tumors
Roche's NTRK Fusion Therapy receives FDA approval, marking a significant advancement in the treatment of solid tumors with NTRK gene fusions.
Executive Summary
- Roche's NTRK Fusion Therapy receives FDA approval, marking a significant advancement in the treatment of solid tumors with NTRK gene fusions.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: March 31, 2026
The U.S. Food and Drug Administration (FDA) has granted approval to entrectinib (Rozlytrek) for the treatment of adult and pediatric patients with NTRK fusion-positive solid tumors. The approval, announced by Roche on August 15, 2023, marks a significant advancement in targeted therapy for patients whose tumors harbor NTRK gene fusions, regardless of tumor type.
Approval Details and Mechanism of Action
Entrectinib is a selective tyrosine kinase inhibitor that targets NTRK1/2/3 gene fusions, which drive tumor growth across various cancer types. The FDA's tissue-agnostic approval was based on pooled data from three pivotal clinical trials: STARTRK-2, STARTRK-1, and ALKA-372-001.
Clinical Trial Results
The integrated analysis demonstrated compelling efficacy across multiple tumor types. Key findings include:
- Overall response rate (ORR) of 57.4% (95% CI: 43.2-70.8)
- Median duration of response (DoR) of 10.4 months (95% CI: 7.1-12.9)
- Complete response rate of 7.4%
- Median progression-free survival of 11.2 months
Safety Profile
The safety analysis, including data from 355 patients, showed a manageable toxicity profile. The most common adverse events (≥20%) included:
- Fatigue (48%)
- Constipation (46%)
- Dysgeusia (44%)
- Edema (40%)
- Dizziness (38%)
Market Impact and Access
Roche has announced immediate commercial availability of entrectinib in the United States. The company is implementing a comprehensive patient support program to facilitate access and provide financial assistance for eligible patients.
Expert Perspectives
"This approval represents a significant advancement in precision medicine," stated Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. "It demonstrates our commitment to advancing targeted therapies that can benefit patients across multiple tumor types."
Frequently Asked Questions
What is NTRK fusion-positive cancer?
NTRK fusion-positive cancers occur when NTRK genes fuse with other genes, leading to abnormal proteins that can cause cancer cell growth. These fusions can occur in various tumor types.
How is NTRK fusion testing performed?
Testing can be done through various methods, including next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), or immunohistochemistry (IHC).
What is the dosing for entrectinib?
The recommended dose is 600 mg orally once daily for adults and is based on body surface area for pediatric patients.
What's Next
Roche continues to evaluate entrectinib in ongoing clinical trials, including studies in additional patient populations and combination therapy approaches. The company is also developing companion diagnostics to identify patients who may benefit from this targeted therapy.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
About the Author
Related Articles
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…